Patient Support Services Contact Us

Investors

News

03/19/19
REDWOOD CITY, Calif. , March 19, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective March 13, 2019 , the compensation committee of the company’s board of directors granted the newly hired Chief Legal Officer an option to buy 225,000 shares of the
Printer Friendly Version
03/18/19
REDWOOD CITY, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Thomas Fitzpatrick as its Chief Legal Officer. Mr. Fitzpatrick brings more than 20 years of executive-level legal experience to his role as leader of Coherus’ legal
Printer Friendly Version
03/18/19
REDWOOD CITY, Calif. , March 18, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that the Centers for Medicare and Medicaid Services (CMS) approved UDENYCA™ (pegfilgrastim-cbqv) biosimilar for transitional pass-through payment status in the hospital outpatient
Printer Friendly Version
02/28/19
REDWOOD CITY, Calif. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today reviewed corporate events and reported financial results for the quarter and full year ended December 31 , 2018.  Fourth Quarter 2018 and Recent Corporate Highlights Include: On November 2, 2018
Printer Friendly Version
02/26/19
REDWOOD CITY, Calif. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare conferences. Management will deliver a company presentation at the 38 th Cowen & Company Healthcare Conference
Printer Friendly Version
02/22/19
REDWOOD CITY, Calif. , Feb. 22, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective February 21, 2019 , the compensation committee of the company’s board of directors granted three new employees options to purchase an aggregate of 47,000 shares of the
Printer Friendly Version
02/14/19
REDWOOD CITY, Calif. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that its fourth quarter and full year 2018 financial results will be released after market close on Thursday, February 28, 2019 . Starting at 4:30 p.m.
Printer Friendly Version
02/07/19
REDWOOD CITY, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective February 6, 2019 , the compensation committee of the company’s board of directors granted three new employees options to purchase an aggregate of 40,000 shares of the
Printer Friendly Version
01/25/19
Complaint alleges Amgen infringes three U.S. patents recently awarded to Coherus REDWOOD CITY, Calif. , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced it has filed suit against Amgen in the United States District Court (
Printer Friendly Version
01/25/19
- The settlement affords U.S. market entry of December 15, 2023 - REDWOOD CITY, Calif. , Jan. 25, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced it has executed settlement agreements with AbbVie Inc.
Printer Friendly Version
01/14/19
REDWOOD CITY, Calif. , Jan. 14, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective January 10, 2019 , the compensation committee of the company’s board of directors granted three new employees options to purchase an aggregate of 68,000 shares of the
Printer Friendly Version
01/07/19
REDWOOD CITY, Calif. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced that it has entered into a $75 million senior secured credit facility agreement with Healthcare Royalty Partners .
Printer Friendly Version
01/02/19
REDWOOD CITY, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Darlene Horton , M.D. as Chief Medical and Regulatory Affairs Officer. She assumed her role on January 1, 2019 . “We are very pleased that Dr.
Printer Friendly Version
01/02/19
REDWOOD CITY, Calif. , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the 37 th annual J.P. Morgan healthcare conference on Tuesday, January 8, 2017 at 7:30 a.m. PT being held in San Francisco .
Printer Friendly Version